CV risk factors

High-Intensity Exercise Safe in Hypertrophic Cardiomyopathy

by

TOPLINE: A 12-week supervised high-intensity exercise programme was feasible for patients with hypertrophic cardiomyopathy (HCM), leading to potential improvements in cardiorespiratory fitness, cardiovascular risk factors, and psychological outcomes, without an increased risk for arrhythmias. METHODOLOGY: This study examined the feasibility and impact of an individualised high-intensity exercise programme in patients with HCM recruited at three … Read more

When Sudden Cardiac Death Happens Without Warning

by

Almost half of people who experience sudden cardiac death were never diagnosed with cardiovascular disease (CVD) before it was too late, warned investigators. “A substantial number of deaths happen in people we don’t see in the cardiac ward,” said Tobias Skjelbred, MD, a cardiologist at Copenhagen University Hospital and lead author of a new nationwide … Read more

SJS/TEN Survivors Show Lasting Cardiovascular Mortality Risk

by

TOPLINE: A study showed that survivors of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) had an increased risk for cardiovascular morbidity and mortality, which peaked within the first year and remained elevated for up to 7 years after the initial SJS/TEN diagnosis. METHODOLOGY: A retrospective study evaluated survivors of SJS/TEN from Taiwan’s National Health … Read more

Feb 21 2025 This Week in Cardiology

by

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast, download the Medscape app or subscribe on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only. … Read more

Unlocking Heart Health: New GLP-1 Research Reveals Cardiovascular Advantages

by

Tirzepatide Shows Promise in Reducing cardiovascular Risk for Obese heart Failure Patients A new analysis of the SUMMIT trial reveals that the glucagon-like peptide 1 (GLP-1) agonist tirzepatide significantly lowers the risk of cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF). This benefit remains consistent nonetheless of whether … Read more

New GLP-1 Data Reinforce CV Benefit

by

The glucagon-like peptide 1 (GLP-1) agonist tirzepatide lowers the risk for cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF), whether they have general adiposity, measured with the body mass index (BMI), or central adiposity, measured with the waist-to-height ratio, showed a new analysis from the SUMMIT trial. This … Read more

Current Lung Function May Signal Future Heart Health

by

TOPLINE: Better lung function, expressed as higher forced vital capacity (FVC), is associated with a reduced risk for the onset of heart disease, diabetes, and stroke over a follow-up period of approximately 10 years, according to a cross-sectional analysis of a population-based study. METHODOLOGY: Researchers conducted a cross-sectional analysis of a population-based study (the BOLD … Read more

Is Intermittent Fasting Safe and Beneficial?

by

Practiced for centuries as a ritual in many religions, intermittent fasting (IF) is rapidly growing in popularity as a weight loss and health-improvement tool. A 2024 survey found that as many as 13% of Americans followed an IF regimen during the previous year. But does it really offer health benefits? And are there any downsides? … Read more

Feb 07 2025 This Week in Cardiology

by

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast, download the Medscape app or subscribe on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only. … Read more

Bleeding Prognoses After Coronary Stenting Unreliable

by

Two scores widely used to determine whether patients are at high risk for bleeding after coronary stenting disagreed in 22% of patients, and one score underestimated the risk, warned investigators comparing the approaches. Bleeding risk is important to know when deciding how long to prescribe dual antiplatelet therapy after percutaneous coronary interventions and how intensive … Read more